United Therapeutics Corporation $UTHR Stock Holdings Decreased by Wellington Management Group LLP

Wellington Management Group LLP lowered its position in shares of United Therapeutics Corporation (NASDAQ:UTHR) by 39.1% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,379,025 shares of the biotechnology company’s stock after selling 885,222 shares during the quarter. Wellington Management Group LLP owned 3.22% of United Therapeutics worth $747,197,000 as of its most recent SEC filing.

Several other hedge funds have also made changes to their positions in the company. Callan Family Office LLC purchased a new stake in United Therapeutics in the 2nd quarter worth about $1,217,000. Leuthold Group LLC lifted its stake in United Therapeutics by 41.4% in the fourth quarter. Leuthold Group LLC now owns 10,672 shares of the biotechnology company’s stock valued at $5,200,000 after acquiring an additional 3,126 shares during the last quarter. UBS Group AG boosted its holdings in United Therapeutics by 45.3% in the fourth quarter. UBS Group AG now owns 225,849 shares of the biotechnology company’s stock worth $110,045,000 after purchasing an additional 70,445 shares in the last quarter. Nicholas Investment Partners LP boosted its stake in shares of United Therapeutics by 478.5% during the 4th quarter. Nicholas Investment Partners LP now owns 4,553 shares of the biotechnology company’s stock worth $2,218,000 after acquiring an additional 3,766 shares in the last quarter. Finally, M&T Bank Corp raised its stake in shares of United Therapeutics by 171.6% in the 4th quarter. M&T Bank Corp now owns 3,142 shares of the biotechnology company’s stock valued at $1,531,000 after acquiring an additional 1,985 shares in the last quarter. Hedge funds and other institutional investors own 94.08% of the company’s stock.

Wall Street Analysts Forecast Growth

UTHR has been the subject of several analyst reports. Royal Bank Of Canada reduced their target price on United Therapeutics from $704.00 to $677.00 and set an “outperform” rating for the company in a report on Thursday, August 6th. JPMorgan Chase & Co. lifted their price target on shares of United Therapeutics from $685.00 to $687.00 and gave the company an “overweight” rating in a research report on Thursday, July 23rd. Bank of America reduced their price objective on shares of United Therapeutics from $620.00 to $613.00 and set a “neutral” rating for the company in a research note on Friday, July 10th. Weiss Ratings downgraded shares of United Therapeutics from a “buy (b)” rating to a “buy (b-)” rating in a report on Thursday. Finally, Wells Fargo & Company upgraded shares of United Therapeutics from an “equal weight” rating to an “overweight” rating and raised their target price for the company from $575.00 to $735.00 in a research note on Thursday, May 7th. Eleven analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat, United Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $646.00.

United Therapeutics Trading Down 2.4%

UTHR opened at $515.46 on Friday. United Therapeutics Corporation has a 1-year low of $303.08 and a 1-year high of $609.35. The stock has a market capitalization of $22.11 billion, a price-to-earnings ratio of 18.44, a P/E/G ratio of 1.75 and a beta of 0.59. The business has a 50 day moving average of $530.46 and a 200-day moving average of $538.70.

United Therapeutics (NASDAQ:UTHR) last announced its earnings results on Wednesday, August 5th. The biotechnology company reported $7.27 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $6.86 by $0.41. United Therapeutics had a net margin of 41.56% and a return on equity of 20.18%. The business had revenue of $783.30 million for the quarter, compared to analyst estimates of $804.65 million. During the same quarter in the previous year, the firm posted $6.41 earnings per share. United Therapeutics’s revenue was down 1.9% compared to the same quarter last year. Equities analysts predict that United Therapeutics Corporation will post 26.33 EPS for the current year.

Insider Buying and Selling at United Therapeutics

In related news, CEO Martine A. Rothblatt sold 9,500 shares of the stock in a transaction dated Wednesday, August 26th. The shares were sold at an average price of $517.28, for a total value of $4,914,160.00. Following the completion of the sale, the chief executive officer owned 324,443 shares in the company, valued at approximately $167,827,875.04. This trade represents a 2.84% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Paul A. Mahon sold 8,300 shares of United Therapeutics stock in a transaction dated Thursday, August 20th. The stock was sold at an average price of $523.14, for a total value of $4,342,062.00. Following the sale, the executive vice president directly owned 45,172 shares in the company, valued at approximately $23,631,280.08. This trade represents a 15.52% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 424,075 shares of company stock worth $227,336,485 over the last 90 days. Company insiders own 8.60% of the company’s stock.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.